Related Experiment Videos

Group A streptococci: evaluation of in vitro resistance to two macrolides

M Millesimo1, D Savoia

  • 1Department of Clinical and Biological Sciences, University of Torino, San Luigi Hospital, Italy.

Microbios
|January 1, 1995
PubMed

Insights

Severe group A Streptococcus infections are rising, possibly due to antibiotic resistance. Clarithromycin showed better activity against Streptococcus pyogenes, but capsule expression may hinder treatment effectiveness.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • An increase in severe group A streptococcal infections has been observed recently.
  • Antibiotic resistance to commonly used drugs like clarithromycin and erythromycin may be linked to therapy failures.

Purpose of the Study:

  • To assess the in vitro relationship between increasing antibiotic resistance and the failure of therapies for streptococcal infections.
  • To evaluate the antimicrobial activity of clarithromycin and erythromycin against Streptococcus pyogenes strains.

Main Methods:

  • Streptococcus pyogenes strains were isolated from children's pharyngotonsillar swabs across different years and from the American Type Culture Collection.
  • In vitro susceptibility testing was performed to evaluate antimicrobial activity against these strains.
  • The impact of M protein presence and capsule expression on drug activity was assessed.

Main Results:

  • Resistance to macrolide antibiotics (clarithromycin and erythromycin) in Streptococcus pyogenes increased from 4% in 1990 to 15.5% in 1994.
  • Clarithromycin demonstrated superior antistreptococcal and bactericidal activity compared to erythromycin.
  • Capsule expression in strains correlated with a slower bactericidal effect, while M protein presence did not significantly alter drug kinetics.

Conclusions:

  • The resurgence of severe group A Streptococcus infections might be associated with increased circulation of encapsulated strains.
  • Capsule expression appears critical for resistance to phagocytic killing, potentially contributing to treatment challenges.
  • Clarithromycin exhibits promising activity, but understanding resistance mechanisms, including capsule's role, is crucial for effective treatment.

Related Concept Videos